Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
US11813257B2 · kind B2 · utility
0Cited by
11References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2021 |
| Grant date | Nov 14, 2023 |
| Priority date | — |
| Expiry date | Oct 29, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.